Digestive Diseases and Sciences

, Volume 47, Issue 10, pp 2139–2150 | Cite as

REVIEW: Genetic Bases of Autoimmune Hepatitis

  • Albert J. Czaja
  • Derek G. Doherty
  • Peter T. Donaldson


Our goal was to review the hypotheses in evolution that promise to elucidate the genetic bases of autoimmune hepatitis. DRB1*0301 and DRB1*0401 are the principal risk factors in Britain and the United States. Other susceptibility alleles in different ethnic groups commonly share the same or a similar motif at the critical DRβ71 position of the HLA class II molecule. Disease severity may be determined by the number of alleles encoding lysine at the DRβ71 position, the density of dimers presenting antigen, and the avidity of T-cell receptors for the displayed antigen. Concurrence on the same or different chromosomes of other nonspecific autoimmune promoters may also contribute. A negatively charged residue at the P4 position of antigenic peptides is preferred for binding to the disease-susceptibility alleles, and this complex may be recognized by promiscuous T cells. We conclude that autoimmune hepatitis is a model by which to study the genetic bases of autoimmunity.

autoimmune hepatitis autoimmunity autoantigens HLA 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Czaja AJ: Autoimmune hepatitis: Evolving concepts and treatment strategies. Dig Dis Sci 40:435–456, 1995Google Scholar
  2. 2.
    Czaja AJ, Manns MP, McFarlane IG, Hoofnagle JH: Autoimmune hepatitis:the investigational and clinical challenges. Hepatology 31:1194–1200, 2000Google Scholar
  3. 3.
    Czaja AJ, Carpenter HA, Santrach PJ, Moore SB: Genetic predispositions for immunological features in chronic liver diseases other than autoimmune hepatitis. J Hepatol 24:52–59, 1996Google Scholar
  4. 4.
    Czaja AJ, Dos Santos RM, Porto A, Santrach PJ, Moore SB: Immune phenotype of chronic liver disease. Dig Dis Sci 43:2149–2155, 1998Google Scholar
  5. 5.
    Czaja AJ, Donaldson PT: Genetic susceptibilities for immune expression and liver cell injury in autoimmune hepatitis. Immunol Rev 174:250–259, 2000Google Scholar
  6. 6.
    Czaja AJ: Immunopathogenesis of autoimmune-mediated liver damage. In Immunology and The Liver: Autoimmunity. R Moreno-Otero, G Clemente-Ricote, C Garcia-Monzon (eds). Madrid, Aran Ediciones, 2000, pp 73–83Google Scholar
  7. 7.
    Czaja AJ: Understanding the pathogenesis of autoimmune hepatitis. Am J Gastroenterol 96:1224–1231, 2001Google Scholar
  8. 8.
    Whitacre CC, Reingold SC, O'Looney PA: A gender gap in autoimmunity. Science 283:1277–1278, 1999Google Scholar
  9. 9.
    Blomberg G, Geckeler WR, Weigert M: Genetics of the antibody response to dextran in mice. Science 177:178–180, 1972Google Scholar
  10. 10.
    Mackay IR, Whittingham S, Tait B: Genetic control of immune responsiveness in man. Vox Sang 32:10–19, 1977Google Scholar
  11. 11.
    Chiovato L, Lapi P, Fiore E, Tonacchera M, Pinchera A: Thyroid autoimmunity and female gender. J Endocrinol Invest 16:384–391, 1993Google Scholar
  12. 12.
    Talal N, Roubinian JR: Sex hormones and autoimmunity. In Genetic Control of Autoimmune Disease. NR Rose, PE Bigazzi, NL Warner (eds). New York, Elsevier-North Holland, 1978, pp 163–174Google Scholar
  13. 13.
    Van Griensven M, Bergijk EC, Baelde JJ, De Heer E, Bruijn JA: Differential effects of sex hormones on autoantibody production and proteinuria in chronic graft-versus-host diseaseinduced experimental lupus nephritis. Clin Exp Immunol 107:254–260, 1997Google Scholar
  14. 14.
    Rowley MJ, Mackay IR: Measurement of antibody-producing capacity in man. I. The normal response to flagellin from Salmonella adelaide. Clin Exp Immunol 5:407–418, 1969Google Scholar
  15. 15.
    Hooper B, Whittingham S, Mathews JD, Mackay IR, Curnow DH: Autoimmunity in a rural community. Clin Exp Immunol 12:79–87, 1972Google Scholar
  16. 16.
    Tomer Y, Shoenfeld Y: The significance of natural autoantibodies. Immunol Invest 17:389–424, 1988Google Scholar
  17. 17.
    Nelson JL. Microchimerism: Implications for autoimmune disease. Lupus 8:370–374, 1999Google Scholar
  18. 18.
    Tanaka A, Lindor K, Ansari A, Gershwin ME: Fetal microchimerisms in the mother: Immunologic implications. Liver Transplant 6:138–143, 2000Google Scholar
  19. 19.
    Lambert NC, Evans PC, Hashizumi TL, Maloney S, Gooley T, Furst DE, Nelson JL: Cutting edge: Persistent fetal microchimerism in T lymphocytes is associated with HLA-DQA1*0501: Implications for autoimmunity. J Immunol 164:5545–5548, 2000Google Scholar
  20. 20.
    Czaja AJ, Carpenter HA, Santrach PJ, Moore SB: Significance of HLA DR4 in type 1 autoimmune hepatitis. Gastroenterology 105:1502–1507, 1993Google Scholar
  21. 21.
    Czaja AJ, Agarwal K, Donaldson PT: Gender effects on clinical expression and outcome of type 1 autoimmune hepatitis: Synergisms with known autoimmune promoters. Gastroenterology 120:A354, 2001 (abstract)Google Scholar
  22. 22.
    Czaja AJ, Manns MP: The validity and importance of subtypes of autoimmune hepatitis: A point of view. Am J Gastroenterol 90:1206–1211, 1995Google Scholar
  23. 23.
    Donaldson PT, Doherty DG, Hayllar KM, McFarlane IG, Johnson PJ, Williams R: Susceptibility to autoimmune chronic active hepatitis: Human leukocyte antigens DR4 and A1-B8-DR3 are independent risk factors. Hepatology 13:701–706, 1991Google Scholar
  24. 24.
    Strettell MDJ, Donaldson PT, Thomson LJ, Santrach PJ, Moore SB, Czaja AJ, Williams R: Allelic basis for HLAencoded susceptibility to type 1 autoimmune hepatitis. Gastroenterology 112:2028–2035, 1997Google Scholar
  25. 25.
    Seki T, Kiyosawa K, Inoko H, Ota M: Association of autoimmune hepatitis with HLA-Bw54 and DR4 in Japanese patients. Hepatology 12:1300–1304, 1990Google Scholar
  26. 26.
    Seki T, Ota M, Furuta S, Fukushima H, Kondo T, Hino K, Mizuki N, Ando A, Tsuji K, Inoko H, Kiyosawa K: HLA class II molecules and autoimmune hepatitis susceptibility in Japanese patients. Gastroenterology 103:1041–1047, 1992Google Scholar
  27. 27.
    Fainboim L, Marcos Y, Pando M, Capucchio M, Reyes GB, Galoppo C, Badia I, Remondino G, Ciocca M, Ramonet M, Fainboim H, Satz ML: Chronic active autoimmune hepatitis in children. Strong association with a particular HLA DR6 (DRB1*1301) haplotype. Hum Immunol 41:146–150, 1994Google Scholar
  28. 28.
    Pando M, Larriba J, Fernandez GC, Fainboim H, Ciocca M, Ramonet M, Badia I, Daruich J, Findor J, Tanno H, Canero-Velasco C, Fainboim L: Pediatric and adult forms of type 1 autoimmune hepatitis in Argentina: Evidence for differential genetic predisposition. Hepatology 30:1374–1380, 1999Google Scholar
  29. 29.
    Vazquez-Garcia MN, Alaez C, Olivo A, Debaz H, Perez-Luque E, Burguete A, Cano S, de la Rosa G, Bautista N, Hernandez A, Bandera J, Torres LF, Kersenobich D, Alvarez F, Gorodezky C: MHC class II sequences of susceptibility and protection in Mexicans with autoimmune hepatitis. J Hepatol 28:985–990, 1998Google Scholar
  30. 30.
    Bittencourt PL, Goldberg AC, Cancado ELR, Porta G, Carrilho FJ, Farias AQ, Palacios SA, Chiarella JM, Abrantes-Lemos CP, Baggio VL, Laudanna AA, Kalil J: Genetic heterogeneity in susceptibility to autoimmune hepatitis types 1 and 2. Am J Gastroenterol 94:1906–1913, 1999Google Scholar
  31. 31.
    Homberg J-C, Abuaf N, Bernard O, Islam S, Alvarez F, Khalil SH, Poupon R, Darnis F, Levy V-G, Grippon P, Opolon P, Bernuau J, Benhamou J-P, Alagille D: Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: A second type of “autoimmune” hepatitis. Hepatology 7:1333–1339, 1987Google Scholar
  32. 32.
    Czaja AJ, Kruger M, Santrach PJ, Moore SB, Manns MP: Genetic distinctions between types 1 and 2 autoimmune hepatitis. Am J Gastroenterol 92:2197–2200, 1997Google Scholar
  33. 33.
    Manns MP, Kruger M: Immunogenetics of chronic liver diseases. Gastroenterology 106:1676–1697, 1994Google Scholar
  34. 34.
    Manns MP, Johnson EF, Griffin KJ, Tan EM, Sullivan KF: Major antigen of liver kidney microsomal autoantibodies in idiopathic autoimmune hepatitis is cytochrome P450db1. J Clin Invest 83:1066–1072, 1989Google Scholar
  35. 35.
    Gueguen M, Yamamoto AM, Bernard O, Alvarez F: Anti-liver kidney microsome antibody type 1 recognizes human cytochrome P450 db1. Biochem Biophys Res Commun 159:542–547, 1989Google Scholar
  36. 36.
    Manns MP, Griffin KJ, Sullivan KF, Johnson EF: LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 monooxygenase. J Clin Invest 88:1370–1378, 1991Google Scholar
  37. 37.
    Zinkernagel RM: MHC-restricted T-cell recognition. The basis of immune surveillance. JAMA 274:1069–1671, 1995Google Scholar
  38. 38.
    Zinkernagel RM, Doherty PC: The discovery of MHC restriction. Immunol Today 18:14–17, 1997Google Scholar
  39. 39.
    Doherty DG, Penzotti JE, Koelle DM, Kwok WW, Lybrand TP, Masewicz S, Nepom GT: Structural basis of specificity and degeneracy of T cell recognition: Pluriallelic restriction of T cell responses to a peptide antigen involves both specific and promiscuous interactions between the T cell receptor, peptide, and HLA-DR. J Immunol 161:3527–3535, 1998Google Scholar
  40. 40.
    Czaja AJ, Santrach PJ, Moore SB: Shared genetic risk factors in autoimmune liver disease. Dig Dis Sci 46:140–147, 2001Google Scholar
  41. 41.
    Brown JH, Jardetsky T, Saper MA, Samraoui B, Bjorkman PJ, Wiley DC: A hypothetical model of the foreign antigen binding site of class II histocompatibility molecules. Nature 332:845–850, 1988Google Scholar
  42. 42.
    Doherty DG, Donaldson PT, Underhill JA, Farrant JM, Duthie A, Mieli-Vergani G, McFarlane IG, Johnson PJ, Eddleston ALWF, Mowat AP, Williams R: Allelic sequence variation in the HLA class II genes and proteins in patients with autoimmune hepatitis. Hepatology 19:609–615, 1994Google Scholar
  43. 43.
    Marsh GE, Bodmer JG: HLA class II nucleotide sequences, 1992. Immunogenetics 37:79–94, 1993Google Scholar
  44. 44.
    Donaldson PT, Manns MP: Immunogenetics of liver disease. In Oxford Textbook of Clinical Hepatology. J Bircher, J-P Benhamou, N McIntyre, M Rizetto, J Rodes (eds). Oxford, Oxford University Press, 1999, pp 173–188Google Scholar
  45. 45.
    Corper AL, Stratmann T, Apostolopoulos V, Scott CA, Garcia KC, Kang AS, Wilson IA, Teyton L: A structural framework for deciphering the link between I-Ag7 and autoimmune diabetes. Science 288:505–511, 2000Google Scholar
  46. 46.
    Nepom GT: A unified hypothesis for the complex genetics of HLA associations with IDDM. Diabetes 39:1153–1157, 1990Google Scholar
  47. 47.
    Sheehy MJ: HLA and insulin-dependent diabetes: A protective perspective. Diabetes 41:123–129, 1992Google Scholar
  48. 48.
    Singal DP, Li J, Zhu Y: Genetic basis for rheumatoid arthritis. Arch Immunol Ther Exp 47:307–311, 1999Google Scholar
  49. 49.
    Singal DP, Li J, Lei K: Genetics of rheumatoid arthritis (RA): Two separate regions in the major histocompatibility complex contribute to susceptibility to RA. Immunol Lett 69:301–306, 1999Google Scholar
  50. 50.
    Toussirot E, Auge B, Tiberghien P, Chabod J, Cedoz JP, Wendling D: HLA-DRB1 alleles and shared amino acid sequences in disease susceptibility and severity in patients from eastern France with rheumatoid arthritis. J Rheumatol 26:1446–1451, 1999Google Scholar
  51. 51.
    Czaja AJ: Frequency and nature of the variant syndromes of autoimmune liver disease. Hepatology 28:360–365, 1998Google Scholar
  52. 52.
    Toussirot E, Auge B, Tiberghien P, Chabod J, Cedoz JP, Wendling D. Autoimmune hepatitis in childhood. A 20 year survey. Hepatology 25:541–547, 1997Google Scholar
  53. 53.
    Miel-Vergani G, Vergani D. Immunological liver diseases in children. Semin Liver Dis 18:271–279, 1998Google Scholar
  54. 54.
    Mieli-Vergani G. Autoimmune sclerosing cholangitis: A distinct clinical entity? J Hepatol 32(suppl 2):7–8, 2000Google Scholar
  55. 55.
    Gregorio GV, Portmann B, Karani J, et al: Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: A 16-year prospective study. Hepatology 33:544–553, 2001Google Scholar
  56. 56.
    Diepolder HM, Jung MC, Keller E, Schraut W, Gerlach JT, Gruner N, Zachoval R, Hoffmann RM, Schirren CA, Scholz S, Pape GR: A vigorous virus-specific CD4+ T cell response may contribute to the association of HLA-DR13 with viral clearance in hepatitis B. Clin Exp Immunol 113:244–251, 1998Google Scholar
  57. 57.
    Lango-Warensjo A, Cardell K, Lindblom B: Haplotypes comprising subtypes of the HLA-DQB1*06 allele direct the antibody response after immunization with hepatitis B surface antigen. Tissue Antigens 52:374–380, 1998Google Scholar
  58. 58.
    Hill A, Allsopp C, Kwiatkowski D, Anstey N, Twumasi P, Rowe P, Bennet S, Brewster D, McMichael AJ, Greenwood BM: Common West African HLA antigens are associated with protection from severe malaria. Nature 352:595–600, 1991Google Scholar
  59. 59.
    Hill A, Allsopp C, Kwiatkowski D, Anstey N, Twumasi P, Rowe P, Bennet S, Brewster D, McMichael AJ, Greenwood BM: Identification of hepatitis A virus as a trigger for autoimmune chronic hepatitis type 1 in susceptible individuals. Lancet 337:1183–1187, 1991Google Scholar
  60. 60.
    Huppertz H-K, Treichel U, Gassel AM, Jeschke R, Meyer zum Buschenfelde K-H: Autoimmune hepatitis following hepatitis A virus infection. J Hepatol 23:204–208, 1995Google Scholar
  61. 61.
    Czaja AJ, Strettell MDJ, Thomson LJ, Santrach PJ, Moore SB, Donaldson PT, Williams R: Associations between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis. Hepatology 25:317–323, 1997Google Scholar
  62. 62.
    Rothbard JB, Gefter ML: Interactions between immunogenic peptides and MHC proteins. Annu Rev Immunol 9:527–565, 1991Google Scholar
  63. 63.
    O'sullivan D, Sidney J, Appella E, Walker L, Phillips L, Colon SM, Miles C, Chesnut RW, Sette A: Characterization of the specificity of peptide binding to four DR haplotypes. J Immunol 145:1799–1808, 1990Google Scholar
  64. 64.
    Garcia K, Degano CM, Pease LR, Huang MD, Peterson PA, Teyton L, Wilson IA: Structural basis of plasticity in T cell receptor recognition of a self peptide MHC antigen. Science 279:1166–1172, 1998Google Scholar
  65. 65.
    Penzotti JE, Doherty DG, Lybrand TP, Nepom GT: A structural model for TCR recognition of the HLA class II shared epitope sequence implicated in susceptibility to rheumatoid arthritis. J Autoimmun 9:287–293, 1996Google Scholar
  66. 66.
    Garboczi DN, Ghosh P, Utz U, Fan QR, Biddison WE, Wiley DC: Structure of the complex between human T-cell receptor, viral peptide and HLA-A2. Nature 384:134–141, 1996Google Scholar
  67. 67.
    Garcia KC, Degano M, Stanfield RL, Brunmark A, Jackson MR, Peterson PA, Teyton L, Wilson IA: An ?? T cell receptor structure at 2.5 angstrom and its orientation in the TCR-MHC complex. Science 274:209–219, 1996Google Scholar
  68. 68.
    Weyland CM, Hicok KC, Goronzy JJ. Nonrandom selection of T cell specificities in anti-HLA-DR responses. Sequence motifs of the responder HLA-DR allele influence T cell recruitment. J Immunol 147:70–78, 1991Google Scholar
  69. 69.
    Yamanaka K, Kwok WW, Mickelson EM, Masewicz S, Nepom GT: T-cell receptor V beta selectivity in T-cell clones alloreactive to HLA-Dw14. Hum Immunol 33:57–64, 1992Google Scholar
  70. 70.
    Czaja AJ, Carpenter HA, Santrach PJ, Moore SB: Genetic predispositions for the immunological features of chronic active hepatitis. Hepatology 18:816–822, 1993Google Scholar
  71. 71.
    Czaja AJ, Rakela J, Hay JE, Moore SB: Clinical and prognostic implications of human leukocyte antigen B8 in corticosteroidtreated severe autoimmune chronic active hepatitis. Gastroenterology 98:1587–1593, 1990Google Scholar
  72. 72.
    Sanchez-Urdazpal L, Czaja AJ, van Hoek B, Krom RAF, Wiesner RH: Prognostic features and role of liver transplantation in severe corticosteroid-treated autoimmune chronic active hepatitis. Hepatology 15:215–221, 1992Google Scholar
  73. 73.
    González-Koch A, Czaja AJ, Carpenter HA, Roberts SK, Charlton MR, Porayko MK, Rosen CB, Wiesner RH: Recurrent autoimmune hepatitis after orthotopic liver transplantation. Liver Transplant 4:302–310, 2001Google Scholar
  74. 74.
    Cookson S, Constantini PK, Clare M, Underhill JA, Bernal W, Czaja AJ, Donaldson PT: Frequency and nature of cytokine gene polymorphisms in type 1 autoimmune hepatitis. Hepatology 30:851–856, 1999Google Scholar
  75. 75.
    Czaja AJ, Cookson S, Constantini PK, Clare M, Underhill JA, Donaldson PT: Cytokine polymorphisms associated with clinical features and treatment outcome in type 1 autoimmune hepatitis. Gastroenterology 117:645–652, 1999Google Scholar
  76. 76.
    Agarwal K, Czaja AJ, Jones DEJ, Donaldson PT: CTLA-4 gene polymorphism and susceptibility to type 1 autoimmune hepatitis. Hepatology 31:49–53, 2000Google Scholar
  77. 77.
    Price P, Witt C, Allcock R, Sayer D, Garlepp M, Kok CC, French M, Mallal S, Christiansen F: The genetic basis for the association of the 8.1 ancestral haplotype (A1, B8, DR3) with multiple immunopathological diseases. Immunol Rev 167:257–274, 1999Google Scholar
  78. 78.
    Agarwal K, Jones DE, Daly AK, James OF, Vaidya B, Pearce S, Bassendine MF: CTLA-4 gene polymorphism confers susceptibility to primary biliary cirrhosis. J Hepatol 32:538–541, 2000Google Scholar
  79. 79.
    Scully LJ, Toze C, Sengar DPS, Goldstein R: Early-onset autoimmune hepatitis is associated with a C4A gene deletion. Gastroenterology 104:1478–1484, 1993Google Scholar
  80. 80.
    Doherty DG, Underhill JA, Donaldson PT, Manabe K, Mieli-Vergani G, Eddleston ALWF, Vergani D, Demaine AG, Williams R: Polymorphism in the human complement C4 genes and genetic susceptibility to autoimmune hepatitis. Autoimmunity 18:243–249, 1994Google Scholar
  81. 81.
    Dugoujon JM, Cambon-Thomsen A: Immunoglobulin allotypes (Gm and Km) and their interactions with HLA antigens in autoimmune diseases: a review. Autoimmunity 22:245–260, 1995Google Scholar
  82. 82.
    Manabe K, Hibberd ML, Donaldson PT, Underhill JA, Doherty DG, Demaine AG, Mieli-Vergani G, Eddleston A1, Williams R: T-cell receptor constant ? germline polymorphisms and susceptibility to autoimmune hepatitis. Gastroenterology 106:1321–1325, 1994Google Scholar
  83. 83.
    Faubion WA, Gores GJ: Death receptors in liver biology and pathobiology. Hepatology 29:1–4, 1999Google Scholar
  84. 84.
    Agarwal K, Czaja AJ, Donaldson PT: Fas (CD95/APO-1) promoter and CCR5 polymorphisms in type 1 autoimmune hepatitis. Hepatology 32:164A, 2000 (abstract)Google Scholar
  85. 85.
    Caplen NJ, Patel A, Millward A, Campbell RD, Ratanachaiyavong S, Wong FS, Demaine AG: Complement C4 and heat shock protein 70 (HSP70) genotypes and type 1 diabetes mellitus. Immunogenetics 32:427–430, 1990Google Scholar
  86. 86.
    Tom W, Farid NR: Reduced C4 in HLA-B8 positive patients with Graves’ disease. Hum Hered 31:227–231, 1981Google Scholar
  87. 87.
    Rittner C, De Marchi M, Mollenhauer E, Carbonara A: Coeliac disease and C4A*Q0: an association secondary to HLADR3. Tissue Antigens 23:130–134, 1984Google Scholar
  88. 88.
    Manns MP, Bremm A, Schneider PM, Notghi A, Gerken G, Prager-Eberle M, Stradmann-Bellinghausen B, Meyer zum Buschenfelde K-H, Rittner C: HLA DRw8 and complement C4 deficiency as risk factors in primary biliary cirrhosis. Gastroenterology 101:1367–1373, 1991Google Scholar
  89. 89.
    Batchelor JR, Fielder AHL, Walport MJ, David J, Lord DK, Davey N, Dodi IA, Malisit P, Wanachiwanawin W, Bernstein R, Mackworth-Young C, Isenberg D: Family study of the major histocompatibility complex in HLA DR3 negative patients with systemic lupus erythematosus. Clin Exp Immunol 70:364–371, 1987Google Scholar
  90. 90.
    Olsen ML, Goldstein R, Arnett FC, Duvic M, Pollack M, Reveille JD: C4A gene deletion and HLA associations in black Americans with systemic lupus erythematosus. J Rheumatol 14:1128–1131, 1987Google Scholar
  91. 91.
    Daniels CA, Borsos T, Rapp HJ, Snyderman R, Notkins AL: Neutralization of sensitized virus by the fourth component of complement. Science 165:508–509, 1969Google Scholar
  92. 92.
    Leijh PC, Van den Barselaar MT, van Zwet TL, Daha MR, van Frith R: Requirement of extracellular complement and immunoglobulin for intracellular killing of microorganisms by human monocytes. J Clin Invest 63:772–784, 1979Google Scholar
  93. 93.
    Schifferli JA, Bartolotti SR, Peters DK: Inhibition of immuneprecipitation by complement. Clin Exp Immunol 42:387–397, 1980Google Scholar
  94. 94.
    Taneja V, David CS: HLA class II transgenic mice as models of human disease. Immunol Rev 169:67–79, 1999Google Scholar
  95. 95.
    Abraham RS, David CS: Identification of HLA-class II restricted epitopes of autoantigens in transgenic mice. Curr Opin Immunol 12:122–129, 2000Google Scholar
  96. 96.
    Wicker LS, Chen S-L, Nepom GT, Elliott JF, Freed DC, Bansal A, Zheng S, Herman A, Lernmark A, Zaller DM, Peterson LB, Rothbard JB, Cumming R, Whiteley PJ: Naturally processed T cell epitopes from human glutamic acid decarboxylase identified using mice transgenic for the type 1 diabetes-associated human MHC class II allele, DRB1*0401. J Clin Invest 98:2597–2603, 1996Google Scholar
  97. 97.
    Fridkis-Hareli M, Rosloniec EF, Fugger L, Strominger JL: Synthetic peptides that inhibit binding of the collagen type II 261-273 epitope to rheumatoid arthritis-associated HLA-DR1 and-DR4 molecules and collagen-specific T-cell responses. Hum Immunol 61:640–650, 2000Google Scholar

Copyright information

© Plenum Publishing Corporation 2002

Authors and Affiliations

  • Albert J. Czaja
    • 1
  • Derek G. Doherty
    • 2
    • 3
  • Peter T. Donaldson
    • 4
  1. 1.Division of Gastroenterology and HepatologyMayo Clinic and Mayo FoundationRochesterUSA
  2. 2.Education and Research CentreSt Vincent’s University HospitalDublin
  3. 3.Institute of Immunology, Department of BiologyNational University of IrelandMaynoothIreland
  4. 4.The Centre for Liver Research, Faculty of Clinical Medical Sciences, The Medical SchoolUniversity of NewcastleNewcastle-upon-TyneUK

Personalised recommendations